We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
REVIEW
[Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
Clinical Calcium 2011 January
Parathyroid hormone-related protein (PTHrP) shares the same receptor (PTH/PTHrP recoptor) with parathyroid hormone (PTH) to generate common intracellular signals. Thus, systemic actions of PTHrP are seemed to be essentially the same as those of PTH, although PTHrP plays its physiological roles in cartilage development and smooth muscle contraction as a local factor. Subcutaneous administration of PTH once a day demonstrates anabolic effects on bone and has been established to be an effective therapeutic modality for patients with severe osteoporosis to increase bone mineral density and then prevent fracture substantially. According to preclinical and some clinical data, daily subcutaneous injection of human PTHrP (1-36) could stimulate bone formation without a substantial increase in bone resorption or expected adverse events such as hypercalcemia. Thus, human PTHrP (1-36) is one of the promising drugs for treatment of osteoporosis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app